As the pioneers of Click-to-Release technology, we use in vivo click chemistry to increase efficacy & decrease toxicity across several systemic treatment modalities.

Green_stripe_long
Purple_stripe_long

Team works

We are led by a seasoned team of researchers, oncologists, and biotech business builders, all motivated by a desire to bring safe, effective treatments to patients.

Purple_stripe_long
Green_stripe_long
Green_stripe_long

Click-to-Release Technology

We have built a leading technology that enables controlled drug release induced by an in vivo click reaction with a trigger molecule with the aim to increase the therapeutic window and utility of potent systemic therapies. Key applications include the on-target activation of antibody-drug conjugates (ADCs) and immunomodulators in the tumor microenvironment, as well as the off-target deactivation of unwanted circulating radiopharmaceuticals.

Purple_stripe_long

Expanding the Therapeutic Potential of ADCs

Conventional ADCs are limited to suitable internalizing targets, which are not necessarily expressed by every cancer type and cancer cell. We are leveraging our Click-to-Release approach to expand the ADC target scope to non- or poorly internalizing receptors and markers. It also enables controlled drug release with a broad bystander effect that makes it possible to kill tumors with heterogenous target expression. Our lead program, TGW101, is a click-cleavable ADC targeting TAG72, a clinically validated non-internalizing target that is widely expressed in solid tumors, but which has so far remained out of reach of current ADC therapies.

Green_stripe_long
Purple_stripe_long

Highlights

October 1, 2024
Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug conjugate (ADC) program for solid tumors into the clinic in 2025
October 1, 2024
Marc Robillard will present the progress of Tagworks click-cleavable radiotherapeutics program at the 6th Targeted Radiopharmaceuticals Summit in Amsterdam on December 5, 2024.
June 22, 2023
Financing round led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures Unique Click-to-Release platform enables on-target activation of antibody-drug conjugates …

Curious about what we do? Get in touch!

Logo-2

About    Our Technology   Pipeline    Join us    News    Contact

Contact
T +31 85 800 8550
info@tagworkspharma.com

Address
Tagworks Pharmaceuticals BV
Toernooiveld 1
6525 ED  Nijmegen
The Netherlands

Stay updated

© Tagworks Pharmaceuticals, 2024 | Terms of use | Design by Ape to Zebra